Therapeutic Substances Regulations 1956 (Amendment)

Overview

The Therapeutic Substances Act 1953, enacted by the Commonwealth Parliament, was designed to regulate the importation, manufacture, and distribution of therapeutic substances within Australia. This legislation aimed to address the need for stringent controls over therapeutic substances to ensure public safety and efficacy. In 1958, Statutory Rules were introduced under this Act to further refine the regulatory framework. The Therapeutic Substances Regulations 1958, made by the Governor-General in accordance with the Act, sought to amend existing regulations to better align with contemporary standards and practices. The policy objective of these regulations was to enhance the oversight and management of therapeutic substances by updating the list of approved laboratories and the substances subject to regulatory scrutiny. The amendments aimed to streamline the processes involved in the examination and analysis of therapeutic substances, ensuring that they meet the required standards before being made available to the public.

Scope and Application

The Therapeutic Substances Regulations, as amended by Statutory Rules 1958, No. 21, apply to the control and regulation of therapeutic substances within the Commonwealth of Australia. These regulations are made under the authority of the Therapeutic Substances Act 1953 and govern the examination, analysis, and certification of therapeutic substances, as well as the appointment of laboratories authorised to conduct these activities. The regulations specifically mention laboratories controlled by the Department of Customs and Excise as being authorised to carry out examinations and analyses. The scope of the regulations extends to ensuring that therapeutic substances meet the required standards for safety and efficacy, and they include amendments that update the list of substances subject to regulation, such as the addition of Procaine Benzylpenicillin to the Schedule. The regulations are applicable across the Commonwealth, with specific amendments made to clarify and update existing provisions without introducing new substantive changes to the jurisdictional reach or application thresholds.

Key Provisions

The Therapeutic Substances Regulations, made under the Therapeutic Substances Act 1953, have been amended by Statutory Rules 1958, No. 21. These regulations primarily involve adjustments to the laboratories responsible for the examination of therapeutic substances and the addition of a new substance to the Schedule. Regulation 11, concerning the appointment of laboratories, has been amended to remove a specific reference to the Commonwealth Laboratory, Department of Customs and Excise, Melbourne, and to include any laboratory controlled by the Department of Customs and Excise (Reg. 11(a) & (b)). This broadens the scope of laboratories authorised to conduct examinations under the Act. The amendments also revise Regulation 15, altering the wording to ensure clarity and precision in the duties of the official analyst. Specifically, the change involves replacing the word "by" with "to" in sub-regulation (2), presumably to clarify the process or procedure the official analyst must follow (Reg. 15). Furthermore, the Schedule to the Therapeutic Substances Regulations has been updated to include "Procaine Benzylpenicillin" following "Plague Vaccine" (Schedule). This addition suggests an expansion in the list of substances regulated under the Act. The obligations imposed by these regulations include ensuring that any laboratory appointed for the examination of therapeutic substances is controlled by the Department of Customs and Excise. This requirement aims to maintain a consistent standard and authority overseeing the testing and certification processes. The inclusion of Procaine Benzylpenicillin in the Schedule mandates that this substance must comply with the regulations governing therapeutic substances, including quality control, labelling, and safety standards. Failure to comply with the Therapeutic Substances Regulations can result in civil and criminal penalties. The Therapeutic Substances Act 1953 outlines various offences, including the unauthorised sale or supply of therapeutic substances, which can lead to fines and imprisonment. While the specific penalties are not detailed in these regulations, the broader Act provides for substantial fines and potential imprisonment for serious or repeated offences. The exact penalties would depend on the nature and severity of the breach, as well as any relevant jurisdictional guidelines.